Miles Fisher – författare

Cardiovascular disease is a common cause of morbidity and mortality in people with diabetes, and it is an issue that is becoming increasingly important to both cardiologists and specialists in diabetes. The routine management of patients with diabetes now includes close attention to the methods to control hyperglycaemia that give maximum reduction in cardiovascular events. This pocketbook details the complications that diabetes presents in relation to heart disease, introduces the reader to various risk factors and discusses the possible treatments that can be explored. This second edition has also been updated throughout to include new trial data, new drugs and updates on treatment of diabetes in heart failure patients. The information in this book is presented in an easy to use format, and supplemented with key figures, tables and summarized research findings.

With cardiovascular disease becoming the most common cause of death in people with diabetes, interest in the assessment and treatment of heart disease in these patients has been reawakened. This book examines developing topics from a largely cardiological perspective, covering both pharmacological and non-pharmacological interventions.  The DIGAMI study on the use of intravenous insulin infusion at the time of myocardial infarction (MI) has stimulated a large number of discussion papers on the best treatment of MI in the diabetic patient. The UKPDS has shown that treatment of Type 2 diabetes does not reduce cardiovascular end-points significantly, but that aggressive treatment of blood pressure can do so. In addition, sub-group analysis from several large cardiovascular trials has shown that treatment with statins, anti-platelet therapy, ACE inhibitors and other drugs will also reduce cardiovascular events in people with diabetes.

DIABETES DRUG NOTES Diabetes is becoming more common in both older and younger generations and in keeping with this escalation in cases, there are an ever increasing number of drugs and drug classes that are suitable to treat hyperglycaemia. In a unique blend of diabetes practice, clinical pharmacology, and cardiovascular medicine, Diabetes Drug Notes describes the principles of clinical pharmacology with regards to diabetes prescribing. Each drug class for the treatment of diabetes is covered in detail, along with the effect on the cardiovascular and renal systems caused by each drug. Building upon the success of their “Drug Notes” series for Practical Diabetes and their “Drugs for Diabetes” series in the British Journal of Cardiology, the team of experts focuses on the glycaemic management of type 1 and type 2 diabetes, with other effects of antidiabetic drugs covered as well. Diabetes Drug Notes also includes: Comprehensive and up-to-date coverage of the drugs for the glycaemic management of patients with type 1 or type 2 diabetesExpert reflection on prescribing considerations for special groups, as well as common pitfalls in prescribingDetailed case histories to illustrate relevant informationSummaries of recent guidelines related to diabetic interventionDiabetes Drug Notes is a user-friendly guide for a general diabetes medical, nursing, and pharmacology readership, as well as those who support them.